Vascular Biogenics (VBLT) Given Daily News Sentiment Score of 0.23
Media stories about Vascular Biogenics (NASDAQ:VBLT) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vascular Biogenics earned a news impact score of 0.23 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3620245109338 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Who Are The Major Shareholders Of Vascular Biogenics Ltd (VBLT)? (finance.yahoo.com)
- VBL Therapeutics to Present at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) on November 18 (finance.yahoo.com)
- BRIEF-VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan (reuters.com)
- BRIEF-VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan (businessinsider.com)
- VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan – Times of India (timesofindia.indiatimes.com)
Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Vascular Biogenics in a research report on Tuesday, November 7th. Chardan Capital upped their price target on shares of Vascular Biogenics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, November 6th. Zacks Investment Research upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. Finally, ValuEngine downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, September 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $16.00.
Vascular Biogenics (VBLT) traded up $0.25 during trading on Monday, reaching $7.65. 224,200 shares of the company’s stock were exchanged, compared to its average volume of 314,428. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.70.
Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. equities research analysts anticipate that Vascular Biogenics will post -0.81 earnings per share for the current year.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.